The leadership of the Prostate Cancer Foundation includes accomplished business leaders, successful entrepreneurs, acclaimed scientists and dedicated philanthropists. Our Leadership Team includes people who have founded and led successful healthcare companies, developed major marketing programs, managed clinical research organizations and raised millions of dollars for philanthropies. Our Board of Directors includes some of the most accomplished CEOs in the country, leaders in entertainment and marketing, outstanding financiers and distinguished academic medical researchers.
Founder and Chairman
Mike Milken has long been at the forefront of successful initiatives in medical research, education, public health, and access to capital. One of America’s leading philanthropists over the past four decades, he was called “The Man Who Changed Medicine” in a Fortune cover story. He formalized his previous philanthropy in 1982 by co-founding the Milken Family Foundation, and in 1993 he launched the Prostate Cancer Foundation. In 2003, when federal research funding slowed, he founded FasterCures with the mission of accelerating progress against all life-threatening diseases. He chairs the Milken Institute, whose annual Global Conference convenes 3,500 decision makers from 50 nations each spring in Los Angeles. In recognition of an Institute gift in 2014, George Washington University announced the renaming of the Milken Institute School of Public Health. As a financier, beginning in 1969, Mike is often said to have revolutionized modern capital markets by expanding access to capital for thousands of growing companies that created millions of jobs. Mike graduated with highest distinction from Berkeley and earned his MBA at Wharton. He and his wife, Lori, were married in 1968 and have three children and nine grandchildren. See http://www.mikemilken.com.
Jonathan W. Simons, MD, is an internationally recognized physician-scientist, oncologist and acclaimed investigator in translational prostate cancer research. Prior to joining PCF in 2007, he was Distinguished Service Professor of Hematology and Oncology at the Emory University School of Medicine and Professor of Biomedical Engineering and Materials Sciences at the Georgia Institute of Technology. Dr. Simons is the Founding Director of the Winship Cancer Institute at Emory University in Atlanta and Co-Director of the National Cancer Institute Center for Cancer Nanotechnology Excellence at Emory and Georgia Tech.
Dr. Simons received a BA from Princeton University and an MD from The Johns Hopkins University School of Medicine. Before entering medical school he was a Rotary International Postgraduate Fellow in the Humanities at the University of Kent in Canterbury, England, and a Nuffield Foundation Fellow in the Department of Biochemistry at the University of Cambridge. Dr. Simons completed his residency in internal medicine at Massachusetts General Hospital at Harvard Medical School and his fellowship in medical oncology at Johns Hopkins. Dr. Simons has been a funded physician-scientist in prostate cancer by the National Cancer Institute, Department of Defense, PCF and other agencies since 1990. He is also board-certified in internal medicine and medical oncology. He is married to Plum Simons, a breast cancer survivor, and has two sons.
Chief Financial Officer, Treasurer and Secretary
Ralph Finerman is a certified public accountant and attorney and serves as president of RFG Financial Group, Inc., a financial consulting firm that specializes in helping clients structure, execute, manage and account for investments in a wide variety of industries. Mr. Finerman received a BS from the Wharton School of the University of Pennsylvania, an LLB from Columbia Law School and an LLM in Taxation from New York University School of Law. Mr. Finerman has been Treasurer and Secretary of the Foundation since its creation in 1993.
STUART HOLDEN, MD
Stuart Holden, MD, is a Health Sciences Clinical Professor in the Department of Urology at the David Geffen School of Medicine at UCLA and Associate Director of the UCLA Institute of Urologic Oncology. Serving as PCF’s Medical Director since the inception of the Foundation in 1993, Dr. Holden directs the medical and scientific strategy of PCF and oversees its grant award programs, consortia activities and scientific meetings. An internationally respected urologic oncologist and surgeon who has worked on the frontlines of prostate cancer for more than 36 years, Dr. Holden introduced radioactive seed implantation to Los Angeles and was an early adopter of ultrasound-guided prostate biopsy. Dr. Holden completed his medical degree and surgical training at New York Hospital Cornell University Medical College; urology residency at Emory University; and fellowships in urology and developmental genetics at Memorial-Sloan Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society.
HOWARD R. SOULE, PhD
Executive Vice President
Chief Science Officer
Howard R. Soule, PhD, coordinates global academic, government and biopharmaceutical sector research activity and is responsible for the implementation of PCF's global research strategies. From 1997 to 2004, he was Executive Vice President and Chief Science Officer of PCF. He is also a member of the Department of Defense Prostate Cancer Research Program Integration Panel. Most recently, he was Managing Director of Knowledge Universe Health and Wellness Group, a private investment firm focused on companies in the general areas of disease prevention and treatment. Dr. Soule has been with the Foundation for 11 years.
Prior to joining PCF in 1997, Dr. Soule was a senior R&D executive for nine years at Corvas International, Inc., a public biotechnology company. He was responsible for the discovery and development of innovative products for the treatment of life-threatening cardiovascular diseases. Dr. Soule has considerable experience in medical diagnostic and device industries as well.
Dr. Soule received a PhD from Baylor College of Medicine in Virology and Epidemiology and was a Post Doctoral Fellow in Immunology and Vascular Biology at the Scripps Research Institute.
BARBARA J. PARSKY
Senior Vice President
Chief Marketing Officer
Barbara J. Parsky is a senior marketing and corporate communications executive with extensive experience in conceiving, executing global corporate marketing communications programs, directing major brand image advertising campaigns and public relations programs, brand strategy development, issues/crisis communications and web site redesign.
Before joining PCF, she had her own corporate consulting business where she counseled executive management on a variety of industry issues, brand reputation and crisis programs. Prior to her consulting business, Barbara was Senior Vice President, Corporate Communications, Edison International as chief communications officer of the Corporation. She was a member of Edison International’s Managing Committee, which sets strategy and policy for the Company. Barbara chaired the Company's corporate Philanthropy Committee, which directs contributions nationwide.
Barbara’s extensive experience came from her long professional association with the General Electric Company (GE)/National Broadcasting Company (NBC). Throughout her 20-year career there, she held several management positions in marketing and communications. At GE, Barbara was manager of Corporate Advertising where she led and directed the brand image program for the "We Bring Good Things to Life” national advertising, public relations and promotion programs. Barbara won a Clio, a prestigious advertising award, for executing a health care commercial for GE imaging products.
Barbara holds a BA from Rollins College in Winter Park, Florida.
Senior Vice President, Finance and Administration
Prior to joining PCF, Ms. Hsieh was the Director of Financial Planning for Vivendi Universal Net USA (an entity created to oversee the U.S. Internet-related companies owned by Vivendi Universal), where she managed the operating plan and monthly forecasts for multiple business units. Prior to the formation of VUNet USA, Ms. Hsieh was the Director of Finance for MP3.com, which was one of the early digital music providers on the Internet. Before that, Ms. Hsieh was the Manager of International Finance for The Walt Disney Company. She holds an MBA from California Polytechnic State University, San Luis Obispo, and a BA in Economics from the University of California, San Diego.
Vice President, Events
Ms. Haber has been with PCF since 1999 and brings over 20 years of event and financial management experience to the organization. Prior to joining PCF, Ms. Haber was the administrator for a private equity investment fund, handling daily security and institutional trading as well as all investor relations. Before that, Ms. Haber spent several years at Pacific Holding Company and Dole Food Company, handling security trading for both privately held and publicly held entities, research and analyses of acquisition candidates, real estate development projects and planning and execution of special events, including political fundraising dinners, golf events and annual shareholder meetings. Ms. Haber received her BA in both Anthropology and Business from the University of California, Los Angeles.
PHILIP KANTOFF, MD
Chairman, PCF Global Research Council
Chairman, Global Treatment Sciences Network
Dana-Farber Cancer Institute
Philip Kantoff, MD received his undergraduate degree and medical degree from Brown University, and was chief resident in Internal Medicine at New York University Hospital/Bellevue Hospital. He spent four years at the National Institutes of Health conducting research in retroviral mediated gene transfer and gene therapy. He completed his medical oncology fellowship training at the Dana-Farber Cancer Institute (DFCI) in 1987. Dr. Kantoff is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. At the DFCI and Brigham and Women’s Hospital, he serves as the Chairman of the Executive Committee for Clinical Research, Director of The Lank Center for Genitourinary Oncology, Vice Chair of Medical Oncology and Chief of the Division of Solid Tumor Oncology. He is the Director of the Prostate Cancer Program and National Cancer Institute sponsored SPORE in Prostate Cancer at Dana-Farber/Harvard Cancer Center. Dr. Kantoff focuses his clinical activities in caring for patients with prostate and testicular cancers. His research is both clinical and translational. His clinical research involves developing improved treatments for patients with genitourinary cancers. His laboratory efforts involve understanding the molecular basis of prostate cancer including mechanisms of resistance to hormonal therapy and genetic determinants of aggressive disease. As Chairman of the Prostate Cancer Foundation’s (PCF) Global Research Council (GRC), Dr. Kantoff advises the leadership of PCF on a wide variety of matters concerning scientific program policy and progress and future direction of the PCF’s research programs and research enterprise in the areas of basic, translational, clinical science and epidemiology. As Chairman of the GRC, Dr. Kantoff leads the GRC members in generating its independent advice to PCF.